Derek Ott
Psychiatry · Los Angeles, CANPI 1710920111
Payments from drug & device makers
Across 1,384 payments — averaging $237.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$105K
- Corium, LLC$55K
- Ironshore Pharmaceuticals Inc.$46K
- Tris Pharma Inc$45K
- AbbVie$25K
- Alkermes, Inc.$12K
- plus $41K from 23 others
What the payments were for
- Consulting fees$16,9765%
- Speaking & faculty fees$250,96676%
- Travel & lodging$28,6689%
- Food & beverage$32,23610%
- Education$1580%
- Gifts$1400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 177 | $105,303 |
| Corium, LLC | 109 | $55,018 |
| Ironshore Pharmaceuticals Inc. | 98 | $46,459 |
| Tris Pharma Inc | 165 | $44,719 |
| AbbVie(2 entities) | 153 | $24,994 |
| Alkermes, Inc. | 72 | $12,147 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 13 | $9,062 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 60 | $8,146 |
| Noven Pharmaceuticals, Inc. | 3 | $7,403 |
| Takeda Pharmaceuticals U.S.A., Inc. | 67 | $2,920 |
| Sunovion Pharmaceuticals Inc. | 98 | $2,593 |
| Vanda Pharmaceuticals Inc. | 68 | $1,757 |
| Johnson & Johnson | 61 | $1,635 |
| Otsuka America Pharmaceutical, Inc. | 59 | $1,597 |
| Lundbeck LLC | 68 | $1,531 |
| Neos Therapeutics, LP | 26 | $1,266 |
| Neurocrine Biosciences, Inc. | 8 | $421 |
| Axsome Therapeutics, Inc. | 11 | $377 |
| Teva Pharmaceuticals USA, Inc. | 12 | $312 |
| Harmony Biosciences LLC | 5 | $261 |
| Adlon Therapeutics L.p. | 14 | $249 |
| Shire North American Group Inc | 10 | $194 |
| Jazz Pharmaceuticals Inc. | 3 | $183 |
| Idorsia Pharmaceuticals US Inc | 5 | $156 |
| Vertical Pharmaceuticals, LLC | 6 | $138 |
| Arbor Pharmaceuticals, Inc. | 6 | $136 |
| Noven Therapeutics, LLC | 5 | $112 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Aytu Biopharma, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$90,193
- Azstarys$53,508
- Dyanavel XR$41,463
- LYBALVI$41,349
- Quillichew ER$32,041
- Quillivant$27,591
- JORNAY PM$27,545
- VRAYLAR$22,477
- Jornay PM 20mg capsules (Bottle of 100)$17,223
- Xelstrym$7,403
- CAPLYTA$7,065
- Quillivant XR$4,450
- ARISTADA$1,419
- TRINTELLIX$1,320
- Adzenys XR-ODT$819
- Cotempla XR-ODT$819
- ARISTADA INITIO$355
- INGREZZA$251
- LATUDA$241
- REXULTI$236
How this compares
$329,144 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 99 | $212,110 |
| Lurasidone Hcl | 136 | $78,551 |
| FanaptIloperidone | 48 | $72,244 |
| VraylarCariprazine Hcl | 34 | $53,142 |
| TrintellixVortioxetine Hydrobromide | 53 | $38,584 |
| VyvanseLisdexamfetamine Dimesylate | 74 | $37,031 |
| CaplytaLumateperone Tosylate | 11 | $36,750 |
| AbilifyAripiprazole | 26 | $26,175 |
| Aripiprazole | 143 | $23,930 |
| Chlorpromazine Hcl | 114 | $15,303 |
| ConcertaMethylphenidate Hcl | 27 | $12,971 |
| Asenapine Maleate | 13 | $11,908 |
| Paliperidone ErPaliperidone | 53 | $9,969 |
| BelsomraSuvorexant | 21 | $9,201 |
| Vilazodone Hcl | 70 | $8,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,597 | $212,11099 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $2,920 | $75,615127 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,757 | $72,24448 claims |
| AbbVieVraylar | $24,994 | $53,14234 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $8,146 | $36,75011 claims |
| Johnson & JohnsonConcerta, Risperdal | $1,635 | $18,40447 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Los Angeles
- Lon SchneiderLos Angeles$1.8M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.